AbbVie Inc.

- AbbVie expects adjusted net interest expense of $2 billion in 2024 to finance the ImmunoGen and Cerevel transactions. - There is acknowledgment of some higher dilution in earnings per share guidance due to the earlier closing of ImmunoGen and the pending acquisition of Cerevel. - The 2024 adjusted earnings per share guidance includes $0.42 of dilution related to these recent and pending acquisitions. - No explicit mention of new fundraising through debt or equity beyond the financing related to the ImmunoGen and Cerevel transactions. - The company focuses on managing existing financing related to acquisitions rather than announcing new fundraising initiatives. In summary, AbbVie's current and near-term debt is primarily related to acquisitions (ImmunoGen and Cerevel), with $2 billion adjusted net interest expense forecasted for 2024; no new fundraising plans beyond this are detailed.

- AbbVie completed the acquisition of ImmunoGen, accelerating entry into the solid tumor market and strengthening the oncology pipeline. - The integration of ImmunoGen has been seamless, highlighting the addition of high-caliber talent. - The pending acquisition of Cerevel is on track to close mid-year, further augmenting the neuroscience portfolio with differentiated assets. - AbbVie is advancing multiple research and development programs, adding novel early-stage programs and partnerships in oncology and immunology. - Continued investment in consumer activation and product launches is planned, especially as the aesthetics market (notably in China) is expected to recover in the second half of 2024. These strategic investments reflect AbbVie's focus on pipeline expansion and market growth beyond Humira.

- AbbVie expects robust revenue growth in 2025, with growth accelerating in 2026 and beyond, supported by Part D benefit redesign and margin expansion (Page 6). - Ex-Humira growth platform delivered >15% revenue growth in Q1 2024, driven by strong performance across key products (Page 1). - Skyrizi and Rinvoq show strong momentum with favorable access anticipated in 2025 and beyond, supporting continued growth (Page 6). - Immunology revenues reached approx. $5.4 billion in Q1 2024, with Skyrizi growing operationally by 48% and rapidly expanding global market share (Page 1). - The aesthetics business expects negative market growth in China near-term but anticipates recovery and continued investment starting mid-year 2024 (Page 8). - Long-term outlook includes a high-single-digit revenue CAGR through the end of the decade, supported by a diversified portfolio and pipeline advancements (Page 1).

- Expect robust revenue growth in 2025 with acceleration in 2026 and beyond due to Part D benefit redesign. - Operating margin expected to expand, typically leading to earnings growth outpacing revenue growth. - Exception in 2025 where net interest expense will reduce earnings growth rate, but solid earnings growth will still be delivered. - Strong ex-Humira growth platform showing momentum with over 15% revenue growth this quarter and double-digit growth in key products. - Raised 2024 adjusted EPS guidance by $0.16 to a range of $11.13 to $11.33, reflecting strong performance. - Long-term outlook expects a high-single-digit revenue CAGR through the end of the decade, supporting sustained earnings growth. - Continued investment in R&D and pipeline expansion will fuel future growth.

The transcript on page 8 and surrounding pages does not provide specific information regarding the current or expected orderbook or pending orders for AbbVie. The discussion primarily focuses on: - Pricing benefits related to formulary changes with CVS and associated volume declines. - Market dynamics for products like Humira, biosimilars, Skyrizi, Rinvoq, and aesthetics in China. - Contracting strategies and expected market performance trends for 2024 and beyond. - Inventory impact in aesthetics (~$50 million in Q1). - No explicit data or commentary about the size or status of the orderbook or pending orders was disclosed. Therefore, there is no available detailed update on current or expected orderbook or pending orders in the provided pages of the call transcript.